Status:
WITHDRAWN
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
Lead Sponsor:
Pfizer
Conditions:
Asthma, Bronchial
Lung Diseases, Obstructive
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study (A7881006) is the first multiple dose study in moderate asthmatic subjects and aims to determine the safety and efficacy of PF-00610355 when subjects take PF-00610355 on a daily basis for 4...
Eligibility Criteria
Inclusion
- Subjects with a physician documented history or diagnosis of persistent asthma for at least 6 months prior to Screening Visit 1.
- Trough FEV1 must be 50-100% of predicted at Screening Visit 1.
- Subjects who have been maintained on a stable dose of ICS over the previous month prior to screening.
Exclusion
- Subjects who have had a severe asthma exacerbation in the 2 months prior to screening.
- Subjects meeting any of the criteria of 'very poorly controlled' according to the NIH EPR 3 guidelines.
- Subjects with evidence or history of cardiovascular disease including angina, myocardial, infarction, clinically significant cardiac arrhythmia (eg, atrial fibrillation, atrial flutter,supraventricular tachycardia, ventricular tachycardia), systemic hypertension (SBP \> 160 mmHg or DBP \>100mmHg), pulmonary hypertension or cerebrovascular disease (including transient ischaemic attacks).
Key Trial Info
Start Date :
April 15 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00830427
Start Date
April 15 2009
End Date
December 31 2009
Last Update
January 31 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.